Background: Little is known about prognostic factors for patients 85 years or older undergoing endoscopic submucosal dissection for early gastric cancer. Therefore, this study aimed to identify such prognostic factors.
Methods: We retrospectively evaluated the long-term outcomes and prognostic factors of 143 patients 85 years or older undergoing endoscopic submucosal dissection for early gastric cancer at a single-center between October 2005 and September 2020. Using the Kaplan-Meier method and a Cox proportional hazards regression model, we examined the relationships of patient characteristics and endoscopic curability (additional gastrectomy recommended [eCuraC-2] or not recommended) with overall survival.
Results: The median age of the patients was 86 years, and most patients were men (65%). The eCuraC-2 rate was 14.7%. During the follow-up period, 55 patients died; however, only two patients died due to gastric cancer. The 3-year and 5-year overall survival rates were 91.5% and 74.7%, respectively. Male sex (hazard ratio, 2.23; 95% confidence interval, 1.16-4.30), American Society of Anesthesiologists Physical Status of 3 (hazard ratio, 2.57; 95% confidence interval, 1.32-4.99), body mass index < 18.9 kg/m (hazard ratio, 2.21; 95% confidence interval, 1.11-4.40), and eCuraC-2 (hazard ratio, 3.04; 95% confidence interval, 1.37-6.75) were identified as independent prognostic factors. Moreover, patients with eCuraC-2 had significantly more poor prognostic factors than those who did not.
Conclusions: The decision to perform endoscopic submucosal dissection for patients with the aforementioned prognostic factors should be carefully considered because follow-up without endoscopic submucosal dissection is possible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00464-024-10935-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Canadian Association of Radiologists Cancer Diagnostic Imaging Referral Guideline.
Can Assoc Radiol J
January 2025
University of Alberta, Edmonton, AB, Canada.
The Canadian Association of Radiologists (CAR) Cancer Expert Panel is made up of physicians from the disciplines of radiology, medical oncology, surgical oncology, radiation oncology, family medicine/general practitioner oncology, a patient advisor, and an epidemiologist/guideline methodologist. The Expert Panel developed a list of 29 clinical/diagnostic scenarios, of which 16 pointed to other CAR guidelines. A rapid scoping review was undertaken to identify systematically produced referral guidelines that provide recommendations for one or more of the remaining 13 scenarios.
View Article and Find Full Text PDFFirst-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Nat Med
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here.
View Article and Find Full Text PDFEvaluating survival outcomes and treatment recommendations in resectable gastric cancer.
Sci Rep
January 2025
Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA.
No consensus exists on the optimal therapy for resectable gastric cancer (GC) and gastroesophageal junction (GEJ) tumors, including the effectiveness of chemoradiotherapy versus perioperative chemotherapy (PC). Our study aimed to compare overall survival (OS) outcomes associated with the recommended treatment modalities for GC and GEJ tumors and evaluate treatment trends from 2010 to 2020. A national registry cohort identified patients with ≥ cT2 nonmetastatic GC and GEJ cancer.
View Article and Find Full Text PDFA prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).
Surg Endosc
January 2025
Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China.
Background: Endoscopic diagnosis of early gastric cancer (EGC) is a challenge. It is not clear whether deep convolutional neural network (DCNN) model could improve the endoscopists' diagnostic performance.
Methods: We established a DCNN-assisted system and found that accuracy of diagnosis is higher than endoscopists.
A large histological images dataset of gastric cancer with tumour microenvironment annotation for AI.
Sci Data
January 2025
Department of Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150081, China.
Gastric cancer (GC) is the third leading cause of cancer death worldwide. Its clinical course varies considerably due to the highly heterogeneous tumour microenvironment (TME). Decomposing the complex TME from histological images into its constituent parts is crucial for evaluating its patterns and enhancing GC therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!